Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 9/20 | 0.43 |
| ▸ | NOS2 | P35228 | 9/20 | 0.43 |
| ▸ | NOS1 | P29475 | 7/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4646183 | 0.79 | NOS2 (0.43) | TDP1NOS3NOS2NOS1BACE1 | |
| SCHEMBL1279214 | 0.79 | KDM4E (0.54) | TDP1ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL5758060 | 0.79 | NOS2 (0.48) | TDP1ALDH1A1TP53CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL4437267 | 0.77 | NOS2 (0.42) | TDP1NOS3NOS2NOS1BACE1 | |
| SCHEMBL2946995 | 0.75 | CYP3A4 (0.40) | TDP1ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL15819694 | 0.75 | CYP3A4 (0.40) | TDP1ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL454523 | 0.72 | MAPT (0.40) | TDP1CYP3A4NOS3NOS2NOS1 | |
| SCHEMBL23580732 | 0.72 | ADORA2A (0.39) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL12113956 | 0.72 | POLB (0.44) | TDP1ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL14385061 | 0.72 | NOS3 (0.39) | TDP1NOS3NOS2NOS1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1576093-A4 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | claimed |
| EP-1753861-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | Dynamis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1576093-A2 | 3-DEOXYGLUCOSONE AND SKIN | Dynamis Therapeutics, Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | claimed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | claimed |
| WO-2003089601-A2 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| EP-3191486-B1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| US-8106064-B2 | administering 1-[2-Chloro-6-(4-methoxy-benzylamino)-pyridin-4-ylmethyl]-6-(3-[1,3]dioxolan-2-yl-5-methyl-phenoxy)-5-isopropyl-1H-pyrimidine-2,4-dione viricide to treat AIDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-01-31 | — | — | US | disclosed |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7749503-B2 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7671019-B2 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | disclosed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003089601-A2 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-1993013775-A1 | DIAMINOPYRIDINE COMPOUNDS FOR THE INHIBITION OF PROTEIN GLYCOSYLATION | THE ROCKEFELLER UNIVERSITY (US) | 1993-07-22 | — | — | WO | disclosed |
| US-5221683-A | Inhibiting advanced clycosylation of target protein | THE ROCKEFELLER UNIVERSITY (US) | 1993-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | FN3K, PDXK, COLGALT1 | TDP1 1427/4885ALDH1A1 927/4885TP53 3400/4885 |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DPM1, G6PD, UGGT1 | TDP1 2030/4885ALDH1A1 383/4885TP53 2877/4885 |
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLRMT, POLR2H | TDP1 143/4885ALDH1A1 2535/4885TP53 2981/4885 |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DPM1, G6PD, UGGT1 | TDP1 2030/4885ALDH1A1 383/4885TP53 2877/4885 |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | AGER, GLA, GALE | TDP1 1357/4885ALDH1A1 357/4885TP53 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.